Switching from Synjardy 12.5/1000 to Xigduo
When switching from Synjardy (empagliflozin 12.5 mg + metformin 1000 mg) to Xigduo (dapagliflozin + metformin), initiate Xigduo 10 mg/1000 mg once daily, maintaining the same metformin dose while substituting the SGLT2 inhibitor component directly.
Switching Algorithm
Step 1: Verify Current Regimen
- Synjardy 12.5/1000 contains empagliflozin 12.5 mg + metformin 1000 mg
- This is typically dosed twice daily (immediate-release) or once daily (XR formulation) 1
Step 2: Select Appropriate Xigduo Dose
- Initiate Xigduo 10 mg/1000 mg once daily (dapagliflozin 10 mg + metformin 1000 mg)
- This maintains the metformin 1000 mg dose while switching SGLT2 inhibitors
- Both empagliflozin and dapagliflozin are SGLT2 inhibitors with similar mechanisms and glucose-lowering efficacy (intermediate to high) 2
Step 3: Timing of Switch
- Direct switch is appropriate - no washout period needed between SGLT2 inhibitors
- If patient was on Synjardy immediate-release (twice daily), transition to Xigduo once daily dosing
- Take Xigduo with the morning meal
Step 4: Pre-Switch Assessment
- Check eGFR: Do not initiate if eGFR <45 mL/min/1.73 m² due to metformin component 1
- Assess volume status: Correct volume depletion before switching due to SGLT2 inhibitor effects 1
- Review cardiovascular/kidney risk: Both agents provide CV and kidney benefits in appropriate populations 2, 3
Key Considerations
Dosing Equivalence
- Empagliflozin 12.5 mg and dapagliflozin 10 mg have comparable glucose-lowering efficacy
- Both reduce HbA1c by approximately 0.5-0.8% when added to metformin 4, 5
- Weight loss effects are similar (2-3 kg) 4
Metformin Component
- Maintain the same total daily metformin dose (1000 mg)
- If switching from Synjardy immediate-release (1000 mg twice daily = 2000 mg total), you would need Xigduo 10/1000 mg twice daily OR adjust to appropriate total daily dose
- Critical clarification needed: If patient takes Synjardy 12.5/1000 twice daily (total metformin 2000 mg/day), consider Xigduo 10/1000 mg twice daily to maintain metformin exposure
Safety Monitoring Post-Switch
- Monitor for genital mycotic infections (3.9-8.6% incidence with dapagliflozin) 5
- Assess for volume depletion - both SGLT2 inhibitors cause osmotic diuresis 2
- Check glucose levels within 1-2 weeks to ensure maintained glycemic control
- Recheck eGFR within 2-4 weeks, especially if baseline eGFR 45-60 mL/min/1.73 m² 1
Common Pitfalls to Avoid
- Don't underdose metformin: Ensure total daily metformin matches previous regimen
- Don't forget sick day planning: Discontinue SGLT2 inhibitors during acute illness, prolonged fasting, or 3-4 days before surgery to reduce DKA risk 2
- Don't ignore contraindications: Both drugs contraindicated if eGFR <30 mL/min/1.73 m² 1
- Don't combine with GLP-1 agonists without considering additive GI effects if planning future intensification 3
Expected Outcomes
Research demonstrates dapagliflozin added to metformin provides sustained glycemic control with HbA1c reductions of 0.5-0.8%, weight loss of 2-3 kg, and systolic BP reductions of 4-6 mmHg over 48 weeks 4, 6. The switch should maintain similar efficacy given comparable SGLT2 inhibitor mechanisms 2.